Loading
AXIN2 (Axin-2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer, Lung cancer and 2 more.
Inhibitor of the Wnt signalling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta-catenin and APC by GSK3B.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Vemurafenib and Cobimetinib. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes genetic literature 0.61, literature 0.96, genetic association 0.87, somatic mutation 0.92, animal model 0.38).
In plain words · AXIN2 (Axin-2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer, Lung cancer and 2 more.
AXIN2 (Axin-2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer, Lung cancer and 2 more.
Inhibitor of the Wnt signalling pathway. Down-regulates beta-catenin.
No product in this corpus aims at AXIN2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA AXIN2: RNA low tissue specificity; high antibody staining in 15 normal tissues; highest cancer staining glioma (7 of 12 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Skin cancer (all types), Lung cancer (all types), Neuroendocrine tumours, Leukaemia); Open Targets associates it with 4 specific cancer types at or above 0.5 (oligodontia-cancer predisposition syndrome, colorectal cancer, AXIN2-related attenuated familial adenomatous polyposis, hereditary neoplastic syndrome). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas AXIN2 tissue; Open Targets ENSG00000168646 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Mai et al, Genomics, 1999, "Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24". Source.
Sources: HGNC HGNC:904 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y2T1 (protein name, function text, keywords and locations (REST API)); CIViC gene AXIN2 (2 evidence items, 0 assertions, 2 variants; diseases: Chronic Lymphocytic Leukaemia, Ganglioglioma (GraphQL API, CC0)); Open Targets ENSG00000168646 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: colorectal cancer 0.73, neuroendocrine neoplasm 0.51, skin cancer 0.54, lung cancer 0.53 (GraphQL API, CC0))
Inhibitor of the Wnt signalling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta-catenin and APC by GSK3B. Location: Cytoplasm (UniProt). Locus 17q24.1 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Bone marrow, Bronchus, Caudate, Cerebellum, Cervix.
RNA cancer enhanced: Colon Adenocarcinoma 74 pTPM, Rectum Adenocarcinoma 77 pTPM.
Medium only: breast cancer, carcinoid, cervical cancer, endometrial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"AXIN2" OR ABSTRACT:"AXIN2" OR TITLE:"axin 2" OR ABSTRACT:"axin 2" OR TITLE:"Axin-2" OR ABSTRACT:"Axin-2" OR TITLE:"MGC126582" OR ABSTRACT:"MGC126582" OR TITLE:"DKFZp781B0869" OR ABSTRACT:"DKFZp781B0869") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AXIN2, not a curated reading list.